文献速递免疫规划

基于VEEV-VSVG重组复制子的PRRSV载体疫苗在仔猪中引发有效免疫应答

PRRSV vector vaccine based on VEEV-VSVG recombinant replicon elicits efficient immune responses in piglets.
PubMed 文献 · Vaccine · 2025-08-05

本研究基于委内瑞拉马脑炎病毒(VEEV)复制子系统构建表达PRRSV GP3、GP4、GP5和M蛋白的载体疫苗,在BHK-21细胞中成功表达且具时间依赖性与传代稳定性,可产生病毒样囊泡。仔猪免疫后诱发强于阴性对照的体液与细胞免疫,攻毒试验中显著降低血清病毒载量、加速病毒血症清除并减少靶组织病毒载量。

要点

  • PRRSV GP3、GP4、GP5和M蛋白在重组复制子感染的BHK-21细胞中成功表达。
  • 载体疫苗在仔猪中引发强于阴性对照组的体液和细胞免疫应答。
  • 攻毒后疫苗组血清病毒载量大幅降低、病毒血症清除加速、靶组织病毒载量下降。

核心结论

  • 基于VEEV复制子表达PRRSV GP3、GP4、GP5和M蛋白的载体疫苗在仔猪中引发有效体液和细胞免疫,攻毒后显示显著保护效果。

研究设计与样本

  • 本研究构建基于VEEV复制子系统表达PRRSV GP3、GP4、GP5和M蛋白的载体疫苗,并在仔猪中评价免疫原性与保护效力。

主要发现

  • PRRSV GP3、GP4、GP5和M蛋白可在感染重组复制子的BHK-21细胞中成功表达,且表达具时间依赖性和传代稳定性。
  • 重组复制子产生具感染性的病毒样囊泡(VLVs),感染后形成大小和形态一致的噬斑。
  • 载体疫苗在仔猪中引发强于阴性对照组的体液和细胞免疫应答。
  • 攻毒实验中,载体疫苗免疫组血清病毒载量大幅降低、病毒血症清除加速、靶组织病毒载量减少。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Porcine Reproductive and Respiratory Syndrome (PRRS) is one of the most significant viral infectious diseases affecting the global swine industry. Eradicating PRRS remains a formidable challenge due to the high genetic diversity and the complexity of the host immune response. Currently, no commercial vaccine provides complete protection against Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) infection. This study aimed to construct a vector vaccine expressing PRRSV GP3, GP4, GP5, and M protein based on the Venezuelan equine encephalitis virus (VEEV) replicon system and to evaluate the immunogenicity in piglets. Here, we demonstrated that PRRSV GP3, GP4, GP5, and M protein could be successfully expressed in BHK-21 cells infected with recombinant replicons. Notably, the expression exhibiting both time-dependence and passage stability. Recombinant replicons produced infectious virus-like vesicles (VLVs), displayed consistent biological traits, forming plaques of uniform size and morphology post-infection. Building upon these characteristics, we developed a PRRSV vector vaccine incorporating these four recombinant replicons and systematically evaluated immunogenicity and protective efficacy. The analysis revealed that the vector vaccine elicited robust humoral and cellular immune responses, in contrast to the negative control group. In challenge experiments, immunization with vector vaccine demonstrated significant protective effects, including a substantial reduction in serum viral loads, accelerated clearance of viremia and decreased viral loads in target tissues.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Rong Z, Jiao M, Tian L, et al. PRRSV vector vaccine based on VEEV-VSVG recombinant replicon elicits efficient immune responses in piglets. Vaccine. 2025. PMID: 40752247. doi:10.1016/j.vaccine.2025.127572

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。